Trials / Terminated
TerminatedNCT00089856
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 626 (actual)
- Sponsor
- Cell Genesys · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapy with allogeneic prostate vaccine | Immunotherapy with allogeneic prostate vaccine |
| DRUG | Chemotherapy (Taxotere and prednisone) | Chemotherapy (Taxotere and prednisone) |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2004-08-18
- Last updated
- 2008-11-05
Locations
126 sites across 8 countries: United States, Belgium, Canada, France, Germany, Netherlands, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00089856. Inclusion in this directory is not an endorsement.